Online Sales Propel Smart Pet Feeder Market with Subscription-Based Innovations
Key players like PETKIT and Dogness focus on innovative solutions, enhancing pet health and convenience for urban owners. Asia's growing markets and IoT advancements fuel demand, despite challenges such as competition and privacy concerns.
Dublin, May 30, 2025 (GLOBE NEWSWIRE) -- The "Smart Pet Feeder Global Market Insights 2025, Analysis and Forecast to 2030, by Manufacturers, Regions, Technology, Application, Product Type" has been added to ResearchAndMarkets.com's offering.
Smart pet feeders have revolutionized pet care, offering automated food dispensing for dogs and cats through features like programmable schedules, app connectivity, integrated cameras, and voice messaging.
Fueled by the growing pet care market, valued at USD 261 billion in 2022, these devices address the needs of urban pet owners with hectic lifestyles. Innovations such as IoT integration and portion control not only boost convenience but also promote better pet health.
The global smart pet feeder market is set to expand, predicted to reach USD 900 million to USD 1.40 billion by 2025, with a compound annual growth rate (CAGR) of 6.5% to 10.3% through 2030.
Regional Analysis
North America: The U.S. leads the market with high pet ownership and tech adoption, while Canada emphasizes premium feeders.
Europe: Germany and the UK exhibit significant demand growth due to urban pet ownership trends.
Asia Pacific: Rapid growth in China and India accompanies burgeoning pet markets, with Japan focusing on tech-integrated feeders.
Rest of the World: Brazil is expanding in pet tech adoption, and Australia prioritizes convenience-centric devices.
Application Analysis
Offline: Growth of 6.4%-10.2% is expected, driven by pet store sales and interest in premium, feature-rich feeders.
Online: A projected growth of 6.6%-10.4% is linked to e-commerce expansion, with emphasis on subscription-based models.
Type Analysis
Dogs: Anticipated growth of 6.6%-10.4% due to portion control requirements, with trends focusing on durable designs.
Cats: Growth projected at 6.5%-10.3%, driven by demand for small-portion feeders, such as Penthouse Paws' innovation in voice messaging.
Others: Expected growth of 6.3%-10.1% for small pets, with advances in compact design.
Key Market Players
PETKIT Australia: App-controlled feeders.
Dogness Group: Specializes in smart pet devices.
Faroro: Offers budget-friendly feeders.
Dokoo: Focuses on camera integration.
Xiaomi: Delivers cost-effective smart solutions.
Aqara: Emphasizes IoT integration.
Market News
In February 2024, Penthouse Paws introduced the Automatic Cat Feeder featuring a 6-liter capacity, voice messaging, and bite-proof cables, enhancing convenience for cat owners.
Porter's Five Forces Analysis
Threat of New Entrants: High, due to low manufacturing barriers and e-commerce facilitation.
Threat of Substitutes: Moderate, as manual feeders provide less convenience.
Bargaining Power of Buyers: High, with demand for affordable, feature-rich devices.
Bargaining Power of Suppliers: Low, with numerous electronics suppliers.
Competitive Rivalry: High, driven by competition on features and pricing.
Market Opportunities and Challenges
Opportunities:
The global pet care market, along with China's robust pet market in 2023, propels demand.
Urbanization, noted by over 100 million pet-owning Chinese households in 2023, fuels the need for automated solutions.
The WHO's pet nutrition focus spurred a 10% increase in health product demand in 2023.
A 15% rise in global IoT device adoption in 2023 underpins smart feeder growth.
Enhancements like cameras and voice messaging improve user engagement.
Emerging Asian markets present additional growth prospects.
Challenges:
High competition squeezes profit margins with low-cost alternatives.
Technical issues, such as app connectivity failures, compromise user trust.
Rural areas have limited adoption, hindering growth prospects.
Supply chain disruptions affect component availability.
Privacy concerns regarding camera features deter some potential users.
Key Topics Covered:
Chapter 1 Executive Summary
Chapter 2 Abbreviation and Acronyms
Chapter 3 Preface
Research Scope
Research Sources
Research Method
Chapter 4 Market Landscape
Market Overview
Classification/Types
Application/End Users
Chapter 5 Market Trend Analysis
Drivers
Restraints
Opportunities
Threats
Chapter 6 Industry Chain Analysis
Upstream/Suppliers Analysis
Smart Pet Feeder Analysis
Downstream Buyers/End Users
Chapter 7 Latest Market Dynamics
Chapter 8 Trading Analysis
Chapter 9 Historical and Forecast Smart Pet Feeder Market in North America (2020-2030)
Chapter 10 Historical and Forecast Smart Pet Feeder Market in South America (2020-2030)
Chapter 11 Historical and Forecast Smart Pet Feeder Market in Asia & Pacific (2020-2030)
Chapter 12 Historical and Forecast Smart Pet Feeder Market in Europe (2020-2030)
Chapter 13 Historical and Forecast Smart Pet Feeder Market in MEA (2020-2030)
Chapter 14 Summary For Global Smart Pet Feeder Market (2020-2025)
Chapter 15 Global Smart Pet Feeder Market Forecast (2025-2030)
Chapter 16 Analysis of Global Key Vendors
PETKIT Australia
Dogness Group
Faroro
Dokoo
Xiaomi
Aqara (Lumi United Technology)
Allflex group
TESLA Solar
Skymee
Pet Marvel Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/zh1ddf
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
3 hours ago
- Business Insider
TruGolf Announces Reverse Stock Split
Salt Lake City, Utah, June 18, 2025 (GLOBE NEWSWIRE) -- TruGolf Holdings, Inc. (NASDAQ: TRUG), a leading provider of golf simulator software and hardware, today announced that it filed an amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-50 reverse stock split of its Class A common stock. The reverse stock split will take effect at 12:01 am (Eastern Time) on June 23, 2025, and the Company's Class A common stock will open for trading on The Nasdaq Capital Market on June 23, 2025 on a post-split basis, under the existing ticker symbol 'TRUG' but with a new CUSIP number 243733409. As a result of the reverse stock split, every fifty shares of the Company's Class A common stock issued and outstanding prior to the opening of trading on June 23, 2025 will be consolidated into one issued and outstanding share. Proportionate adjustments will be made to the exercise prices and the number of shares underlying the Company's outstanding equity awards, as applicable, as well as to the number of shares issuable under the Company's equity incentive plans. The Class A common stock issued pursuant to the reverse stock split will remain fully paid and non-assessable. The reverse stock split will not affect the number of authorized shares of Class A common stock or the par value of the Class A common stock. No fractional shares will be issued if, as a result of the reverse stock split, a stockholder would become entitled to a fractional share because the number of shares of Class A common stock they hold before the reverse stock split is not evenly divisible by the split ratio. Instead, the stockholder will be entitled to receive a cash payment in lieu of a fractional share. As a result of the reverse stock split, the number of shares of Class A common stock outstanding will be reduced from approximately 40.5 million shares to approximately 0.8 million shares, and the number of authorized shares of Class A common stock will remain at 650 million shares. About TruGolf, Inc. Since 1983, TruGolf has been passionate about driving the golf industry with innovative indoor golf solutions. TruGolf builds products that capture the spirit of golf. TruGolf's mission is to help grow the game by attempting to make it more Available, Approachable, and Affordable through technology - because TruGolf believes Golf is for Everyone. TruGolf's team has built award-winning video games ("Links"), innovative hardware solutions, and an all-new e-sports platform to connect golfers around the world with E6 CONNECT. Since TruGolf's beginning, TruGolf has continued to attempt to define and redefine what is possible with golf technology. Forward-Looking Statements This news release contains certain statements that constitute 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements that are not of historical fact constitute 'forward-looking statements' and accordingly, involve estimates, assumptions, forecasts, judgements and uncertainties. Forward-looking statements include, without limitation, the timing of the reverse stock split. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors. Any forward-looking statements contained in this release speak only as of its date. The Company undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with the SEC, which are available on the SEC's website,
Business Insider
3 hours ago
- Business Insider
TruGolf Announces Acquisition of mlSpatial
Salt Lake City, Utah, June 11, 2025 (GLOBE NEWSWIRE) -- TruGolf Holdings, Inc. (NASDAQ: TRUG), a leading golf technology company, has announced that it has executed a definitive agreement to acquire mlSpatial, a renowned AI and machine learning engineering firm. This strategic acquisition aims to advance the integration of artificial intelligence within TruGolf's industry-leading products, including the Apogee Launch Monitor, Launchbox, Multisport Arcade, and E6 Apex. The collaboration between TruGolf and mlSpatial began in March 2024 with a licensing agreement to co-develop an AI engine enhancing the 9-axis spin accuracy of TruGolf's Apogee Launch Monitor. Building upon this successful partnership, the full acquisition of mlSpatial will enable TruGolf to seamlessly incorporate advanced AI technologies across its entire product suite, delivering unparalleled user experiences, training suggestions, and player insights. 'We are very excited to bring mlSpatial and its AI and machine learning technology into the TruGolf family,' said Chris Jones, TruGolf CEO. He continued, 'Acquiring mlSpatial marks a significant milestone in our commitment to revolutionize golf simulation through cutting-edge AI integration. This acquisition empowers us to explore innovative applications of AI across our ecosystem, enhancing realism and interactivity for our users while lowering development costs.' Josh Pomazal, founder of mlSpatial, expressed enthusiasm about the acquisition: "We're excited to leverage TruGolf's extensive real-time data, collected daily, to continually refine our products with the advanced machine learning and AI models we've developed over the years." This acquisition solidifies our deep commitment to innovation and aligns with the broader industry trend of significant investments in AI infrastructure. Notably, in January 2025, President Donald Trump announced a private-sector initiative, the Stargate Project, aiming to invest up to $500 billion in AI infrastructure within the United States. This substantial investment underscores the rapid progress and importance of AI technologies across various sectors. TruGolf's acquisition of mlSpatial positions the company at the forefront of AI-driven innovation in golf simulation, promising enhanced performance and immersive experiences for enthusiasts worldwide. For more information, please visit About TruGolf Holdings TruGolf is a golf technology company, committed to making golf, easy. From innovative uses for AI to build content and enhance its image and spatial analysis, to gamified golf improvement plans, TruGolf is an industry leader in the growing technological revolution in the sport of golf. Since its founding, TruGolf has redefined what is possible in golf through technology. TruGolf's suite of Hardware, Software, and Web Products make it easier to Play, Improve, and Enjoy the game of golf. Forward-Looking Statements Some of the statements in this release are forward-looking statements, which involve risks and uncertainties. Forward-looking statements include, without limitation, whether the Company's compliance plan will be accepted by Nasdaq and the Company's expected future cash needs. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors. Any forward-looking statements contained in this release speak only as of its date. The Company undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with the SEC, which are available on the SEC's website,
Business Upturn
6 hours ago
- Business Upturn
Novo Nordisk: Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA
By GlobeNewswire Published on June 21, 2025, 04:38 IST Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA Results from the phase 3b STEP UP trial showed that a higher dose of Wegovy ® (semaglutide 7.2 mg) delivered 21% weight loss in people with obesity, with a third of participants losing 25% or more of their weight, compared to placebo 1 (semaglutide 7.2 mg) delivered 21% weight loss in people with obesity, with a third of participants losing 25% or more of their weight, compared to placebo Safety and tolerability of the higher dose of Wegovy ® (semaglutide 7.2 mg) was consistent with the currently approved dose (semaglutide 2.4 mg) 1 (semaglutide 7.2 mg) was consistent with the currently approved dose (semaglutide 2.4 mg) The STEP UP data add to the existing evidence base on the value of Wegovy® in delivering significant weight loss and health gains for people living with obesity Bagsværd, Denmark, 21 June 2025 – Novo Nordisk today presented the results from the phase 3b STEP UP trial in people with obesity without diabetes at the American Diabetes Association (ADA) Scientific Sessions, in Chicago, US. In the STEP UP trial, the higher dose of Wegovy® (semaglutide 7.2 mg) demonstrated a mean weight loss of 21%, with a third of participants losing 25% or more of their body weight compared to placebo at 72 weeks.1 'The STEP UP trial demonstrated that we can increase the dose of semaglutide and achieve greater weight loss than previously seen, and in line with semaglutide's established safety profile. This may offer another option to people who do not attain their weight goals,' said Sean Wharton, lead study author and medical director of the Wharton Medical Clinic, Canada. 'We are already aware that semaglutide can have health benefits for people with heart disease, liver disease, knee osteoarthritis, type 2 diabetes and prediabetes. These findings help to give patients with obesity more options for improvements in their weight and overall health.' STEP UP co-primary endpoints at 72 weeks *1 : semaglutide 7.2 mg semaglutide 2.4 mg PlaceboWeight loss 20.7% 17.5% 2.4% 5% or more weight loss 93.2% 92.5% 35.7% When evaluating the effect of treatment regardless of treatment adherence, people receiving semaglutide 7.2 mg achieved 18.7% weight loss vs 3.9% with placebo, and 90.7% achieved 5% or more weight loss with semaglutide 7.2 mg vs 36.8% on placebo. 'With these results, semaglutide reaffirms its significant weight loss for people with obesity. The STEP UP trial delivers a substantial weight loss of over 20%, in addition to health benefits previously demonstrated with semaglutide,' said Ludovic Helfgott, executive vice president of Product & Portfolio Strategy at Novo Nordisk. 'As pioneers in obesity, we continue to develop new innovative treatments to fit the needs and preferences of people living with obesity. This includes maximising the value of semaglutide for individuals, healthcare systems and society, and developing a new oral formulation of Wegovy® that, pending FDA approval, can become the first GLP-1 pill to offer double-digit weight loss.' In the STEP UP trial, semaglutide 7.2 mg demonstrated a well-tolerated safety profile consistent with previous Novo Nordisk semaglutide trials.1 The most common adverse events were gastrointestinal, and the vast majority were mild to moderate during dose escalation and diminished over time, consistent with the GLP-1 class.1 In STEP UP, 3.3% of people treated with semaglutide 7.2 mg discontinued due to gastrointestinal adverse events, compared to 2.0% with semaglutide 2.4 mg and 0% with placebo.1 Novo Nordisk expects to file the higher dose of Wegovy® for a label update in the EU in the second half of 2025, followed by regulatory submissions in other markets where Wegovy® is already approved. STEP UP selected confirmatory secondary endpoints at 72 weeks * 1 : semaglutide 7.2 mg semaglutide 2.4 mg Placebo10% or more weight loss 86.0% 77.6% 20.0%15% or more weight loss 70.4% 57.5% 7.9%20% or more weight loss 50.9% 35.1% 2.9% 25% or more weight loss 33.2% 16.7% 0% * Based on the trial product estimand: treatment effect if all people adhered to treatment. About the STEP UP trials Novo Nordisk has completed two trials, STEP UP and STEP UP T2D, investigating the efficacy and safety of semaglutide 7.2 mg in people with obesity with or without type 2 diabetes. The 72-week STEP UP trial was a randomised, double-blinded, parallel-group, placebo-controlled, superiority trial designed to evaluate the efficacy and safety of semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo as an adjunct to lifestyle intervention. The trial included 1,407 adults with a BMI ≥30 kg/m2 without diabetes. The primary objective was to demonstrate superiority of semaglutide 7.2 mg against placebo on weight loss. Key confirmatory secondary endpoints included the number of participants achieving 10%, 15%, 20% and 25% weight loss, respectively. The 72-week STEP UP T2D trial investigated semaglutide 7.2 mg in 512 adults with obesity and type 2 diabetes, with the primary objective to demonstrate superiority of semaglutide 7.2 mg against placebo on weight loss. About Wegovy® Semaglutide 2.4 mg is marketed under the brand name Wegovy®. In the EU, Wegovy® is indicated as an adjunct to a reduced calorie diet and increased physical activity for weight management in adults with a BMI of 30 kg/m2 or greater (obesity) or adults with a BMI of 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition. In the EU, Wegovy® is also indicated for paediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater for age and gender (obesity) and body weight above 60 kg. The clinical section of the label also includes data on Wegovy® major adverse cardiovascular events (MACE) risk reduction, improvements in HFpEF-related symptoms and physical function, as well as pain reduction related to knee osteoarthritis. In the US, Wegovy® is indicated in combination with a reduced calorie diet and increased physical activity to reduce the risk of MACE in adults with established cardiovascular disease and either obesity or overweight, as well as to reduce excess body weight and maintain weight reduction long term in paediatric patients aged 12 years and older with obesity and in adults with obesity or with overweight in the presence of at least one weight-related comorbid condition. About Novo Nordisk Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. For more information, visit , Facebook , Instagram , X , LinkedIn and YouTube . Contacts for further information References Wharton, S, et al. (2025). Once-weekly semaglutide 7.2 mg in adults with obesity: the randomised, controlled, phase 3b STEP UP trial. 1966-LB poster. American Diabetes Association (ADA) 85th Scientific Sessions, Chicago, US, June 20 – 23, 2025.17. Attachment Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
